Search Result

Results for "

ligand binding domain (LBD)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Estrogen Receptor/ERR (4) Histone Methyltransferase (5) iGluR (1) Isotope-Labeled Compounds (2) Nuclear Hormone Receptor 4A/NR4A (5) Parasite (5) PPAR (4) ROR (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Endocrinology (1) Infection (5) Inflammation/Immunology (6) Metabolic Disease (7) Neurological Disease (6)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Discoidin Domain Receptor Penicillin-binding protein (PBP) Epigenetic Reader Domain Target Protein Ligand-Linker Conjugates E3 Ligase Ligand-Linker Conjugates FKBP FABP Transthyretin (TTR) Ligands for Target Protein for PROTAC YB-1 WDR5 PD-1/PD-L1 PIKfyve BCL6 P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1322A

Amodiaquine Maximum Cited Publications 9 Publications Verification Amodiaquin	Nuclear Hormone Receptor 4A/NR4A Parasite Histone Methyltransferase	Infection Neurological Disease Inflammation/Immunology
Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to **Nurr1-LBD (ligand binding domain) with an EC₅₀** of ~20 μM. Anti-inflammatory effect .

HY-B1322

Amodiaquine dihydrochloride dihydrate Maximum Cited Publications 9 Publications Verification Amodiaquin dihydrochloride dihydrate	Nuclear Hormone Receptor 4A/NR4A Parasite Histone Methyltransferase	Infection Neurological Disease Inflammation/Immunology
Amodiaquine dihydrochloride dihydrate (Amodiaquin dihydrochloride dihydrate), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine dihydrochloride dihydrate is also a Nurr1 agonist and specifically binds to **Nurr1-LBD (ligand binding domain) with an EC₅₀** of ~20 μM. Anti-inflammatory effect .

HY-B1322B

Amodiaquine dihydrochloride Maximum Cited Publications 9 Publications Verification Amodiaquin dihydrochloride	Nuclear Hormone Receptor 4A/NR4A Parasite Histone Methyltransferase	Infection Neurological Disease Inflammation/Immunology
Amodiaquine dihydrochloride (Amodiaquin dihydrochloride), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor with a K_i of 18.6 nM. Amodiaquine dihydrochloride is also a Nurr1 agonist and specifically binds to **Nurr1-LBD (ligand binding domain) with an EC₅₀** of ~20 μM. Anti-inflammatory effect .

HY-N12840

Logmalicid B

Others Metabolic Disease

Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

Logmalicid B	Others	Metabolic Disease
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

HY-117727

Leriglitazone MIN-102; Hydroxypioglitazone	PPAR	Metabolic Disease
Leriglitazone (MIN-102; Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K_i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC₅₀ of 680 nM .

HY-117727A

Leriglitazone hydrochloride MIN-102 hydrochloride; Hydroxypioglitazone hydrochloride	PPAR	Metabolic Disease
Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K_i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC₅₀ of 680 nM .

HY-120210

XY018	ROR	Inflammation/Immunology Cancer
XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD) .

HY-B1322AS

Amodiaquine-d10	Parasite Histone Methyltransferase	Infection Neurological Disease Inflammation/Immunology
Amodiaquine-d₁₀ is the deuterium labeled Amodiaquine. Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect[1][2][3][4].

HY-B1322AS1

Amodiaquine-d10 hydrochloride Amodiaquin-d₁₀	Nuclear Hormone Receptor 4A/NR4A Parasite Histone Methyltransferase Isotope-Labeled Compounds	Infection Neurological Disease Inflammation/Immunology
Amodiaquine-d₁₀ hydrochloride is deuterated labeled Amodiaquine (HY-B1322A). Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to **Nurr1-LBD (ligand binding domain) with an EC₅₀** of ~20 μM. Anti-inflammatory effect .

HY-111254

GQ-16	PPAR	Metabolic Disease
GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of PPARγ, exhibiting a K_i of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain .

HY-117727S

Leriglitazone-d4 MIN-102-d₄; Hydroxypioglitazone-d₄	Isotope-Labeled Compounds PPAR	Metabolic Disease
Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

HY-132205

DS45500853	Estrogen Receptor/ERR	Metabolic Disease
DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

HY-143201

DS20362725	Estrogen Receptor/ERR	Metabolic Disease
DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

HY-136242

UT-34	Androgen Receptor	Endocrinology Cancer
UT-34 is a potent, selective and orally active second-generation pan-androgen receptor (AR) antagonist and degrader with IC₅₀s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively. UT-34 binds to ligand-binding domain (LBD) and function-1 (AF-1) domains and requires ubiquitin proteasome pathway to degrade the AR. UT-34 has anti-prostate cancer efficacy .

HY-137818

SR19881

Estrogen Receptor/ERR Cardiovascular Disease

SR19881 is a potent dual agonist of ERRγ and ERRβ, with EC₅₀ values of 0.39 and 0.63 μM, respectively .

SR19881	Estrogen Receptor/ERR	Cardiovascular Disease
SR19881 is a potent dual agonist of ERRγ and ERRβ, with EC₅₀ values of 0.39 and 0.63 μM, respectively .

HY-141551

GNE-274	Estrogen Receptor/ERR	Cancer
GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding sites, while GDC-0927 do not. GNE-274 is a potent inhibitor of ER-ligand binding domain (LBD). GNE-274 can be used for cancer research .

HY-W677684

Nurr1 agonist 2	Nuclear Hormone Receptor 4A/NR4A	Others
Nurr1 agonist 2 (Compound 7) is a Nurr1 agonist (EC₅₀: 0.07 μM). Nurr1 agonist 2 binds to the recombinant Nurr1 ligand binding domain (LBD) with a K_d value of 0.14 μM. Nurr1 agonist 2 increases the Nurr1-regulated genes tyrosine hydroxylase (TH) and vesicular amino acid transporter 2 (VMAT2) mRNA expression .

HY-122742

HBT1	iGluR	Neurological Disease
HBT1 is a potent α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor (AMPA-R) potentiator. HBT1 bonds with S518 in the ligand-binding domain (LBD) of AMPA-R in a glutamate-dependent manner. HBT1 did not show remarkable bell-shaped response in brain-derived neurotrophic factor (BDNF) production in primary neurons .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12840

Logmalicid B	Structural Classification Iridoids Cornaceae Cornus officinalis Sieb. et Zucc. Terpenoids Source classification Plants	Others
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

Cat. No.	Product Name	Chemical Structure

HY-B1322AS

Amodiaquine-d10
Amodiaquine-d₁₀ is the deuterium labeled Amodiaquine. Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect[1][2][3][4].

HY-B1322AS1

Amodiaquine-d10 hydrochloride
Amodiaquine-d₁₀ hydrochloride is deuterated labeled Amodiaquine (HY-B1322A). Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to **Nurr1-LBD (ligand binding domain) with an EC₅₀** of ~20 μM. Anti-inflammatory effect .

Amodiaquine-d10 hydrochloride

Amodiaquine-d₁₀ hydrochloride is deuterated labeled Amodiaquine (HY-B1322A). Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC₅₀ of ~20 μM. Anti-inflammatory effect .

HY-117727S

Leriglitazone-d4
Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks